CRT, ICD Therapies Benefit Heart Failure Patients of All Races
(HealthDay News) – For patients with heart failure with reduced ejection fraction, cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillator (ICD) therapies are associated with clinical benefit, irrespective of patient race/ethnicity, according to a study published in the August 26 issue of the Journal of the American College of Cardiology.
Boback Ziaeian, MD, from the David Geffen School of Medicine at the University of California Los Angeles, and colleagues examined the clinical effectiveness of CRT and IDT therapies as a function of race/ethnicity. Data were obtained for outpatients with heart failure with reduced ejection fraction from the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting.
The researchers found that the ICD/cardiac resynchronization defibrillator (CRT-D)-eligible cohort included 7,748 patients (44%, 9%, and 47%non-Hispanic white, non-Hispanic black, and other racial/ethnic minorities or race-not-documented patients, respectively). The cardiac resynchronization pacemaker (CRT-P)/CRT-D-eligible cohort included 1,188 patients (50%, 8%, and 41% non-Hispanic white, non-Hispanic black, and other/not-documented patients, respectively). Clinical benefit was seen in association with ICD/CRT-D therapy (adjusted odds ratio, 0.64; P=0.0002 for 24-month mortality), with similar benefit regardless of race/ethnicity (device-race/ethnicity interaction P=0.7861). Mortality benefit was also seen for CRT-P/CRT-D therapy (adjusted odds ratio, 0.55; P=0.0222), independent of race/ethnicity (device-race/ethnicity interaction P=0.5413).
"Device therapies should be offered to eligible heart failure patients, without modification based on race/ethnicity," the authors write.
Several authors disclosed financial ties to pharmaceutical and medical device companies, including Medtronic, which funded the study.